Exact Sciences (EXAS)
(Delayed Data from NSDQ)
$49.67 USD
+2.62 (5.57%)
Updated Jul 16, 2024 04:00 PM ET
After-Market: $49.67 0.00 (0.00%) 6:32 PM ET
4-Sell of 5 4
D Value F Growth A Momentum D VGM
Brokerage Reports
Exact Sciences Corporation [EXAS]
Reports for Purchase
Showing records 121 - 140 ( 367 total )
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
Upgrading to Buy - Strong Commercial Momentum on Increasing Coverage, DTC
Provider: Roth Capital Partners, Inc.
Analyst: LEWIS C
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
Healthcare - Med Tech Preannouncement Watch - Look for News into Next Week?s JPM Conference
Provider: Roth Capital Partners, Inc.
Analyst: LEWIS C
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
3Q Tops Expectations as 2016 Volume Guidance Reaffirmed
Provider: Roth Capital Partners, Inc.
Analyst: LEWIS C
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
Sector Analysis Update: Molecular Diagnostics: Does the Turnaround have ''''Legs''''?
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: GRISEWOOD S
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
Dropping Coverage Due to Analyst Departure
Provider: WEDBUSH SECURITIES INC.
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
2Q Beat, Unchanged 2016 Outlook Still Back-End Heavy
Provider: Roth Capital Partners, Inc.
Analyst: LEWIS C
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
Cologuard Included in Final USPSTF CRC Guidelines
Provider: Roth Capital Partners, Inc.
Analyst: LEWIS C
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
Leaked JAMA Article Indicates Potentially Positive USPSTF Development
Provider: Roth Capital Partners, Inc.
Analyst: LEWIS C
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
1Q Inline, 2016 Outlook Reaffirmed but Implies Significant 2H16 Ramp
Provider: Roth Capital Partners, Inc.
Analyst: LEWIS C
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
Downgrading to Neutral on 2016 Outlook Viability
Provider: Roth Capital Partners, Inc.
Analyst: LEWIS C
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
Med Tech Preannouncement Watch - Look for News into Next Week?s JPM Conference
Provider: Roth Capital Partners, Inc.
Analyst: LEWIS C
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
Reset Expectations w/ Light 2016 Guide; USPSTF Uncertainties Linger
Provider: Roth Capital Partners, Inc.
Analyst: LEWIS C